Percentage of cancer patients aged 18 years and older treated with high- or moderate-emetic-risk antineoplastic agents who are administered appropriate pre-treatment antiemetic therapy
Category: Quality Measures
Oncology: Screening and Achieving Resolution or Improvement of Distress for Cancer Care
Percentage of patients 18 years and older with an active cancer diagnosis who are screened for distress AND if screen is positive, achieve resolution or improvement within 6 months for at least 1 of their concerns.
THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE:
1) Patients 18 years and older with an active cancer diagnosis who are screened for distress using a comprehensive, standardized tool which assesses physical, emotional, social, practical, and spiritual concerns.
AND
2) Patients 18 years and older with an active cancer diagnosis who screen positive for distress using a comprehensive, standardized screening tool and achieve resolution or improvement within 6 months for at least 1 of their concerns.
The measure contains two submission criteria which aim to identify patients who were screened for distress (Submission Criteria 1) and of those patients who screened positive for distress, did corresponding interventions following a positive distress screening lead to meaningful improvement or resolution within 6 months (Submission Criteria 2). By separating this measure into various submission criteria, the MIPS eligible clinician or practice will be able to better ascertain where gaps in performance exist and identify opportunities for improvement. For accountability reporting in the CMS MIPS program, the rate for Submission Criteria 2 is used for performance.
Use of Peripheral Nerve Block within the Emergency Department in Patients Admitted with Low Energy Hip Fracture
Percentage of patients aged 65 years and older that receive a peripheral nerve block for analgesia following diagnosis of isolated hip fracture within the Emergency Department
Appropriate Follow-up Recommendations for Ovarian-Adnexal Lesions using the Ovarian-Adnexal Reporting and Data System (O-RADS)
The percentage of final reports for female patients receiving a transvaginal ultrasound (US) examination of the pelvis (including transabdominal/transvaginal exams) where a lesion is detected, in which the radiologist describes the lesion using ORADS Lexicon Descriptors, provides ORADS score, and subsequently makes the correct clinical management recommendation based on the ORADS Risk Stratification and Management System.
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate bowel preparation
Percentage of patients recommended for repeat screening or surveillance colonoscopy or an alternate tier 1 or tier 2 colorectal cancer screening modality within one year or less due to inadequate bowel preparation quality
Dihydropyrimidine Dehydrogenase (DPD) Deficiency Testing Prior to Fluoropyrimidine Treatment
Percentage of patients receiving fluoropyrimidine treatment who were tested for dihydropyrimidine dehydrogenase (DPD) deficiency prior to the initial initiation of treatment
Oncology: Advance Care Planning in Metastatic Cancer Patients
Percentage of patients with metastatic (stage 4) cancer who have a documented Advance Care Planning discussion in the first 6 months after metastatic diagnosis to inform treatment decisions and end-of-life care.
Oncology: Patient-Reported Pain Improvement
Percentage of cancer patients currently receiving chemotherapy or radiation therapy who report significant pain improvement (high to moderate, moderate to low, or high to low) within 30 days.
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life
Percentage of patients receiving supportive care drugs (including colony stimulating factors, bone health, supplemental iron medications, and neurokinin 1 (NK1) receptor antagonist antiemetics) during the 14 days prior to and including the date of death.
Patients Suffering From an Upper Extremity Injury who Improve Pain
Percentage of patients 18 years or older suffering from an upper extremity injury who achieve the Minimal Clinically Important Difference (MCID) in the Numeric Pain Rating Scale, or like mapped measure during the performance year.
Additionally, a risk-adjusted MCID proportional difference determined by calculating the difference between the risk model predicted and observed MCID proportion will be reported for each PT/OT/MSK Provider/Group. The risk adjustment will be calculated using a logistic regression model using: baseline function score, baseline pain score, age, sex, payer, surgical status, and symptom duration (time from surgery or symptom onset to baseline physical therapy visit) as well as instrument tool used. These measures will serve as a PT/OT/MSK Provider performance measure at the eligible PT/OT/MSK Provider or group level.
This measure will include one rate:
1) The overall performance rate of non-surgical and surgical patients who achieve the MCID in the Numeric Pain Rating Scale like mapped measure.